{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:03:11Z","timestamp":1752537791834,"version":"3.41.2"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2000,2]]},"DOI":"10.1023\/a:1005444006042","type":"journal-article","created":{"date-parts":[[2002,12,21]],"date-time":"2002-12-21T17:25:23Z","timestamp":1040491523000},"page":"265-271","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of Helicobacter pylori Infection in Clinical Practice in the United States"],"prefix":"10.1007","volume":"45","author":[{"given":"David J.","family":"Kearney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Brousal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"222094_CR1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1523-5378.1996.tb00003.x","volume":"1","author":"RWM van der Hulst","year":"1996","unstructured":"van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ: Treatment of Helicobacter pylori infection: A review of the world literature. Helicobacter 1:6-19, 1996","journal-title":"Helicobacter"},{"key":"222094_CR2","first-page":"2","volume":"93","author":"MB Fennerty","year":"1998","unstructured":"Fennerty MB: Should we abandon metronidazole contaiinng Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. Am J Gastroenterol 93:2-3, 1998","journal-title":"Am J Gastroenterol"},{"key":"222094_CR3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1440-1746.1996.tb00078.x","volume":"11","author":"PD Midolo","year":"1996","unstructured":"Midolo PD, Lambert JR, Turnidge J: Metronidazole resistance: A predictor of failure of Helicobacter pylori eradication by triple therapy. J Gastroenterol Hepatol 11:290-292, 1996","journal-title":"J Gastroenterol Hepatol"},{"key":"222094_CR4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2036.1994.tb00304.x","volume":"8","author":"JG Penston","year":"1994","unstructured":"Penston JG: Helicobacter pylori eradication-understandable caution but no excuse for inertia. Aliment Pharmacol Ther 8:369-389, 1994","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2036.1994.tb00303.x","volume":"8","author":"GNJ Tytgat","year":"1994","unstructured":"Tytgat GNJ: Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 8:359-368, 1994","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR6","first-page":"A14","volume":"112","author":"MB Fennerty","year":"1997","unstructured":"Fennerty MB, Lieberman DL, Magaret N, Consortium AG: Effectiveness of H. pylori treatment regimens in clinical practice: A community-based outcomes study. Gastroenterology 112:A14, 1997","journal-title":"Gastroenterology"},{"key":"222094_CR7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJM199510123331508","volume":"333","author":"JH Walsh","year":"1995","unstructured":"Walsh JH, Peterson WL: The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 333:984-991, 1995","journal-title":"N Engl J Med"},{"key":"222094_CR8","doi-asserted-by":"crossref","unstructured":"Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 41:8-13, 1997","DOI":"10.1136\/gut.41.1.8"},{"key":"222094_CR9","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0016-5085(97)80027-3","volume":"113","author":"P Unge","year":"1997","unstructured":"Unge P: What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 113:S131-S148, 1997","journal-title":"Gastroenterology"},{"key":"222094_CR10","doi-asserted-by":"crossref","first-page":"A340","DOI":"10.1016\/S0016-5085(98)81378-4","volume":"114","author":"R Yang","year":"1998","unstructured":"Yang R, Hamamoto R, Laine L: 1-Week vs 2-week bismuth subsalicylate-based triple therapy for H. pylori: Results of a US randomized trial. Gastroenterology 114:A340, 1998","journal-title":"Gastroenterology"},{"key":"222094_CR11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1046\/j.1365-2036.1996.95267000.x","volume":"10","author":"AF Goddard","year":"1996","unstructured":"Goddard AF, Spiller RC: One-week low-dose triple therapy is preferable to classical bismuth based triple therapy. Aliment Pharmacol Ther 10:1009-1013, 1996","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.1998.00212.x","volume":"93","author":"F Lerang","year":"1998","unstructured":"Lerang F, Moum B, Ragnhildstveit E, Sandvei PK, Tolas P, Whist JE, Henriksen M, Haug JB, Berge T: Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: Experience from clinical practice in a population with a high frequency of metronidazole resistance. Am J Gastroenterol 93:212-216, 1998","journal-title":"Am J Gastroenterol"},{"key":"222094_CR13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2036.1995.tb00410.x","volume":"9","author":"TG Reilly","year":"1995","unstructured":"Reilly TG, Ayres RC, Poxon V, Walt RP: Helicobacter pylori eradication in a clinical setting: Success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 9:483-490, 1995","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0016-5085(98)70541-4","volume":"114","author":"American Gastroenterological Association Medical Position Statement","year":"1998","unstructured":"American Gastroenterological Association Medical Position Statement: Evaluation of dyspepsia. Gastroenterology 114:579-581, 1998","journal-title":"Gastroenterology"},{"key":"222094_CR15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","volume":"272","author":"NIH Consensus Conference","year":"1994","unstructured":"NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. JAMA 272:65-69, 1994","journal-title":"JAMA"},{"key":"222094_CR16","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/0016-5085(89)91616-8","volume":"96","author":"DJ Evans","year":"1989","unstructured":"Evans DJ, Evans DG, Graham DY, Klein PD: A sensitive and specific serologic test for detection of Campylobacter pylori infection. Gastroenterology 96:1004-1008, 1989","journal-title":"Gastroenterology"},{"key":"222094_CR17","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1128\/jcm.34.5.1147-1152.1996","volume":"34","author":"PA Marchildon","year":"1996","unstructured":"Marchildon PA, Ciota LM, Zamaniyan FZ, Peacock JS, Graham DY: Evaluation of three commercial enzyme immunoassays compared with the 13C urea breath test for detection of Helicobacter pylori infection. J Clin Microbiol 34:1147-1152, 1996","journal-title":"J Clin Microbiol"},{"key":"222094_CR18","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1128\/jcm.30.12.3146-3150.1992","volume":"30","author":"NJ Talley","year":"1992","unstructured":"Talley NJ, Kost L, Haddad A, Zinsmeister AR: Comparison of commercial serological tests for detection of Helicobacter pylori antibodies. J Clin Microbiol 30:3146-3150, 1992","journal-title":"J Clin Microbiol"},{"key":"222094_CR19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1128\/jcm.29.8.1635-1639.1991","volume":"29","author":"NJ Talley","year":"1991","unstructured":"Talley NJ, Newell DG, Ormand JE, Carpenter HA, Wilson WR, Zinsmeister AR, Perez-Perez GI, Blaser MJ: Serodiagnosis of Helicobacter pylori: Comparison of enzyme-linked immunosorbent assays. J Clin Microbiol 29:1635-1639, 1991","journal-title":"J Clin Microbiol"},{"key":"222094_CR20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jcp.49.5.373","volume":"49","author":"MH Wilcox","year":"1996","unstructured":"Wilcox MH, Dent THS, Hunter JO, Gray JJ, Brown DFJ, Wight DGD, Wraight EP: Accuracy of serology for the diagnosis of Helicobacter pylori infection-a comparison of eight kits. J Clin Pathol 49:373-376, 1996","journal-title":"J Clin Pathol"},{"key":"222094_CR21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2036.1996.721101000.x","volume":"10","author":"M Dalla Libera","year":"1996","unstructured":"Dalla Libera M, Pazzi P, Carli G, Gamberini S, Scagliarini R, Merighi A, Gullini S: High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. Aliment Pharmacol Ther 10:203-206, 1996","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2036.1997.00230.x","volume":"11","author":"L Laine","year":"1997","unstructured":"Laine L, Frantz JE, Baker A, Neil GA: A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther 11:913-917, 1997","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.1995.tb00374.x","volume":"9","author":"MM Yousfi","year":"1995","unstructured":"Yousfi MM, El-Zimaity HMT, Al-Assi MT, Cole RA, Genta RM, Graham DY: Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 9:209-212, 1995","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(95)92962-2","volume":"345","author":"W de Boer","year":"1995","unstructured":"de Boer W, Driessen W, Jansz A, Tytgat G: Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 345:817-820, 1995","journal-title":"Lancet"},{"key":"222094_CR25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/gut.37.4.477","volume":"37","author":"TJ Borody","year":"1995","unstructured":"Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H: Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 37:477-481, 1995","journal-title":"Gut"},{"key":"222094_CR26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1523-5378.1996.tb00028.x","volume":"1","author":"WA de Boer","year":"1996","unstructured":"de Boer WA, van Etten RJ, Lai JY, Schneeberger PM, van de Wouw BA, Driessen WM: Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter 1:145-150, 1996","journal-title":"Helicobacter"},{"key":"222094_CR27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/bmj.305.6852.502","volume":"305","author":"SW Hosking","year":"1992","unstructured":"Hosking SW, Ling TKW, Yung MY, et al: Randomised controlled trial of short term treatment to eradicate H. pylori in patients with duodenal ulcer. Br Med J 305:502-504, 1992","journal-title":"Br Med J"},{"key":"222094_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2036.1997.87259000.x","volume":"11","author":"G Vautier","year":"1997","unstructured":"Vautier G, Scott BB: A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. Aliment Pharmacol Ther 11:107-108, 1997","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0300-2977(97)00056-9","volume":"52","author":"WA de Boer","year":"1998","unstructured":"de Boer WA, van Etten RJ, Schneeberger PM: Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. Neth J Med 52:10-15, 1998","journal-title":"Neth J Med"},{"key":"222094_CR30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1523-5378.1996.tb00027.x","volume":"1","author":"T Lind","year":"1996","unstructured":"Lind T, Veldhuyzen van Zanten S, Unge P, Spiller R, Bayerdorffer E, O'Morain C, Bardhan KD, Bradette M, Chiba N, Wrangstadh M, Cederberg C, Idstrom JP: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 study. Helicobacter 1:138-144, 1996","journal-title":"Helicobacter"},{"key":"222094_CR31","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/gut.41.6.735","volume":"41","author":"JJ Misiewicz","year":"1997","unstructured":"Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O'Morain C, Cooper BT, Kerr GD, Dixon MF, Langworthy H, Piper D: One week triple therapy for Helicobacter pylori: A multicentre comparative study. Lansoprazole Helicobacter study group. Gut 41:735-739, 1997","journal-title":"Gut"},{"key":"222094_CR32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0016-5085(99)70119-8","volume":"116","author":"T Lind","year":"1999","unstructured":"Lind T, Megraud F, Unge P, Bayerdorffer E, O'Morain C, Spiller R, Veldhuyzen Van Zanten S, Dev Bardhan K, Hellblom M, Wrangstadh M, Zeijlon L, Cederberg C: The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253, 1999","journal-title":"Gastroenterology"},{"key":"222094_CR33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.0953-0673.1996.00275.x","volume":"10","author":"BH Jaup","year":"1996","unstructured":"Jaup BH, Norrby A: Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection. Aliment Pharmacol Ther 10:275-277, 1996","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2036.1997.80252000.x","volume":"11","author":"J Labenz","year":"1997","unstructured":"Labenz J, Idstrom JP, Tillenburg B, Peitz U, Adamek RJ, Borsch G: One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. Aliment Pharmacol Ther 11:89-93, 1997","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2036.1998.00290.x","volume":"12","author":"HJ O'Connor","year":"1998","unstructured":"O'Connor HJ, McLoughlin R, Kelly S, Laundon J, Cunnane K: Lansoprazole triple therapy for Helicobacter pylori-is 5 days enough? Aliment Pharmacol Ther 12:273-276, 1998","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1523-5378.1996.tb00047.x","volume":"1","author":"H Schwartz","year":"1996","unstructured":"Schwartz H, Krause R, Siepman N, Haber M, Weissfeld A, Kidd S, Rose P, Sahba B: Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: A short report. Helicobacter 1:251-255, 1996","journal-title":"Helicobacter"},{"key":"222094_CR37","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1046\/j.1365-2036.1996.111282000.x","volume":"10","author":"L Laine","year":"1996","unstructured":"Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G: Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 10:1029-1033, 1996","journal-title":"Aliment Pharmacol Ther"},{"key":"222094_CR38","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/archinte.158.15.1651","volume":"158","author":"MB Fennerty","year":"1998","unstructured":"Fennerty MB, Kovacs TO, Krause R, Haber M, Weissfeld A, Siepman N, Rose P: A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 158:1651-1656, 1998","journal-title":"Arch Intern Med"},{"key":"222094_CR39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1440-1746.1998.01557.x","volume":"13","author":"N Dal Bo","year":"1998","unstructured":"Dal Bo N, Di Mario F, Battaglia G, Buda A, Leandro G, Vianello F, Kusstatscher S, Salandin S, Pilotto A, Cassaro M, Vigneri S, Rugge M: Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: One or two weeks? J Gastroenterol Hepatol 13:288-293, 1998","journal-title":"J Gastroenterol Hepatol"},{"key":"222094_CR40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1523-5378.1996.tb00012.x","volume":"1","author":"P Moayyedi","year":"1996","unstructured":"Moayyedi P, Langworthy H, Shanahan K, Tompkins DS, Dixon MF, Chalmers DM, Axon AT: Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. Helicobacter 1:71-74, 1996","journal-title":"Helicobacter"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005444006042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1005444006042\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1005444006042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T02:54:55Z","timestamp":1752461695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1005444006042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["222094"],"URL":"https:\/\/doi.org\/10.1023\/a:1005444006042","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}